1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine

Request For Quotation
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine manufacturers

  • SKOG102
  • SKOG102 pictures
  • $2180.00
  • 2026-05-11
  • CAS:21062-28-2
  • Purity:
  • Supply Ability: 10g
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Basic information
Product Name:1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine
Synonyms:1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine;1-(3,4-Dichlorophenyl)-3-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-2-pyrimidinyl]guanidine;WR-81844;Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[(1-ethyl-3-piperidinyl)amino]-6-methyl-2-pyrimidinyl]-;SKOG102
CAS:21062-28-2
MF:C19H25Cl2N7
MW:422.35
EINECS:
Product Categories:
Mol File:21062-28-2.mol
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Structure
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Chemical Properties
Boiling point 573.54°C (rough estimate)
density 1.1768 (rough estimate)
refractive index 1.6300 (estimate)
pka8.80±0.10(Predicted)
Safety Information
MSDS Information
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Usage And Synthesis
UsesSKOG102 is a potent OLIG2 inhibitor that is directly engaging OLIG2 and interferes with the ability of OLIG2 to bind DNA. SKOG102 can be used for the research of glioblastoma (GBM)[1].
in vivo

SKOG102 (10-20 mg/kg; i.p.) inhibits GBM4 tumor growth in mice[1].
SKOG102 (5 mg/kg; i.p.) accumulates in the tumor even over a relatively brief time period and the plasma and brain concentrations are almost identical at 4 hours after injection in mice[1].

Animal Model:NSG mice were inoculated in each flank with GBM4 cells[1]
Dosage:10, 15, and 20 mg/kg; dissolved in solutol:PEG400:water (20%:40%:40%)
Administration:Intraperitoneal injection; first 2 weeks (from day 33 to 46) 10 mg/kg, third week (from day 47 to 54) 15 mg/kg, fourth week (from 55 to 66) first 3 days 20 mg/kg, 2 days break, then alternate days from day 60 to 66
Result:Significantly attenuated tumor growth.
References[1] Tsigelny IF, et, al. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. Oncotarget. 2017 Apr 4;8(14):22370-22384. DOI:10.18632/oncotarget.5633
1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Preparation Products And Raw materials
Tag:1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine(21062-28-2) Related Product Information
Anti-cancer compound library Urea, N-(3,4-dichlorophenyl)-N'-[4-[[3-(dimethylamino)propyl]amino]-6-methyl-2-pyrimidinyl]-